U.S. SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549


                                   FORM 10-QSB


[X]  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
     ACT OF 1934

                For the quarterly period ended September 30, 2003

[ ]  TRANSITION  REPORT  PURSUANT  TO  SECTION  13 OR 15(d)  OF THE  SECURITIES
     EXCHANGE ACT OF 1934

                         For the transition period from

                          Commission File No. 000-15243

                         VITAL HEALTH TECHNOLOGIES, INC.
        (Exact name of small business issuer as specified in its charter)

           Minnesota                                         41-1618186
(State or other jurisdiction of                           (I.R.S. Employer
 incorporation or organization)                           Identification No.)


             9454 Wilshire Blvd., Suite 600, Beverly Hills, CA 90212
                    (Address of Principal Executive Offices)

                                 (310) 278-3108
                          (Issuer's telephone number)

      (Former name, address and fiscal year, if changed since last report)

Check whether the issuer (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for
such shorter period that the issuer was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
Yes [X] No [ ]

Indicate  by check mark  whether  the  registrant  is an  accelerated  filer (as
defined in Rule 12b-2 of the Act). Yes [ ] No [X]


APPLICABLE ONLY TO CORPORATE ISSUERS:

State the number of shares outstanding of each of the issuer's classes of common
equity, as of November 14, 2003: 3,741,250 shares of common stock.

Transitional Small Business Format: Yes  [ ]    No  [X]

<PAGE>

                                   FORM 10-QSB



                         VITAL HEALTH TECHNOLOGIES, INC.




                                      INDEX
                                                                            Page

PART I.      FINANCIAL INFORMATION                                             3

Item 1       Financial Statements                                              3

Item 2       Management's Discussion and Analysis of Financial Condition
             and Plan of Operation                                             7

Item 3       Controls and Procedures

PART II.     OTHER INFORMATION                                                 8

Item 6       Exhibits and Reports on Form 8-K
                                                                               8
             SIGNATURES
                                                                               9
             CERTIFICATION STATEMENTS



Item 1.     Financial Information




<PAGE>

                         VITAL HEALTH TECHNOLOGIES, INC
                          (A DEVELOPMENT STAGE COMPANY)
                      CONDENSED CONSOLIDATED BALANCE SHEETS
                                  (Unaudited)

<TABLE>
<CAPTION>

                                                                     September 30,                 December 31,
                                   ASSETS                                2003                         2002
                                   ------                         ---------------------       ------------------

Current assets:

<S>                                                                           <C>                      <C>
     Cash                                                                     $ 24,828                 $ 11,019
     Prepaid expenses                                                                -                      235
     Accounts receivable                                                        93,001                        -
                                                                  ---------------------       ------------------
         Total current assets                                                  117,829                   11,254

Other assets:                                                                   16,663                        -
                                                                  ---------------------       ------------------

         Total assets                                                        $ 134,492                 $ 11,254
                                                                  =====================       ==================

                      LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
     Accounts payable and accrued expenses                                     $ 4,889                 $ 16,105
     Notes payable                                                                   -                   97,500
                                                                  ---------------------       ------------------

         Total current liabilities                                               4,889                  113,605

Long term liabilities                                                          298,246                        -

         Total Liabilities                                                     308,024                  113,605
                                                                  ---------------------       ------------------

Stockholders' equity:
     Undesignated stock: 5,000,000 shares authorized
         none issued and outstanding                                                 -                        -
     Common stock $.01 par value; 50,000,000 shares authorized;
         shares issued and outstanding 3,741,250 in 2003 and
         3,741,250 in 2002                                                      37,413                   37,413
     Paid-in capital                                                        12,112,629               12,125,310
     Subscription receivable                                                    (6,660)                (110,000)
     Accumulated deficit                                                   (11,793,637)             (11,793,637)
     Deficit accumulated during the development stage                         (523,277)                (361,437)
                                                                  ---------------------       ------------------

         Total stockholders' equity                                           (173,532)                (102,351)
                                                                  ---------------------       ------------------

         Total liabilities and stockholders' equity                          $ 134,492                 $ 11,254
                                                                  =====================       ==================
</TABLE>



<PAGE>
                         VITAL HEALTH TECHNOLOGIES, INC.
                          (A DEVELOPMENT STAGE COMPANY)
                 CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
                                  (Unaudited)

<TABLE>
<CAPTION>
                                             Three Months Ended                 Nine Months Ended      Reentrance to development
                                                September 30,                     September 30,                stage to
                                            2003             2002             2003            2002        September 30, 2003
                                        -----------      -----------      -----------      -----------    ------------------


<S>                                     <C>              <C>              <C>              <C>              <C>
Revenues                                $    10,500      $        --      $    10,500      $        --      $   106,861

Cost of sales                                    --               --               --               --              (38)

General and administrative expenses         (33,285)         (11,073)        (111,653)         (63,270)        (899,144)

Interest expense                                 --           (2,437)         (56,123)          (7,731)        (158,266)

Other income (expense)                           --               --               --               --           (7,404)

Debt forgiveness                                 --               --               --               --          435,243

Income tax expense                               --               --               --               --             (529)
                                        -----------      -----------      -----------      -----------      -----------

Net in Total other income                   (22,785)         (13,510)        (157,276)         (71,001)        (523,277)

Other comprehensive income                       --               --               --               --               --
                                        -----------      -----------      -----------      -----------      -----------

Comprehensive income (loss)             $   (22,785)     $   (13,510)     $  (157,276)     $   (71,001)     $  (523,277)
                                        ===========      ===========      ===========      ===========      ===========



Basic earnings (loss) per share         $     (0.01)     $     (0.00)     $     (0.04)     $     (0.02)     $     (0.14)
                                        ===========      ===========      ===========      ===========      ===========

Weighted average number of shares
     outstanding                          3,741,250        3,740,710        3,741,250        3,740,710        3,741,250
                                        ===========      ===========      ===========      ===========      ===========
</TABLE>


<PAGE>


                         VITAL HEALTH TECHNOLOGIES, INC
                          (A DEVELOPMENT STAGE COMPANY)
                   CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
                                  (Unaudited)

<TABLE>
<CAPTION>
                                                                             Nine months ended        From reentrance to
                                                                               September 30,          development stage to
                                                                            2003           2002       September 30, 2003
                                                                         -----------   ------------   ------------------
<S>                                                                      <C>              <C>              <C>
Cash flows from operating activities:
     Net income (loss)                                                   $(157,276)       $ (71,001)       $(523,277)

     Adjustments to reconcile net income to net cash
        provided by (used in) operating activities:
        Debt forgiveness                                                   (88,920)              --         (524,163)
        Indebtedness incurred for services and storage                          --               --          400,000
        Implied compensation under SABS-T                                       --           10,000          130,000
        Stock issued for services                                               --           23,100           23,100
        Warrents issued for consulting services                                 --               --            2,012
        Depreciation                                                            --              726            2,672
        Valuation allowance                                                     --             (726)           6,878
        Inventory                                                               --               --               38
        Accounts receivable                                                (93,001)              --          (93,001)
        Organization expenses                                              (16,663)              --          (16,663)
        Prepaid expenses                                                       235               --              235
        Accounts payable and other current liabilities                     (11,216)           3,984           (5,909)
                                                                         ---------        ---------        ---------
               Net cash (used in) operating activities                    (366,841)         (33,917)        (598,078)
                                                                         ---------        ---------        ---------
Cash flows used for investing activities:
                                                                                --               --               --
                                                                         ---------        ---------        ---------

               Net cash provided by (used in) investing activities              --               --               --
                                                                         ---------        ---------        ---------

Cash flows from financing activities:
     Stock proceeds                                                         14,641           50,000          144,255
     Decrease (increase) in subscriptions receivable                       165,262               --           17,489
     Issuance of convertible notes payable                                      --           10,000          167,038
     Principal payments                                                                     (15,000)         (15,000)
     Increase in long term debt                                            200,747               --          298,247
                                                                         ---------        ---------        ---------

               Net cash provided by (used in) financing activities         380,650           45,000          612,029
                                                                         ---------        ---------        ---------

Net increase (decrease) in cash and cash equivalents                        13,809           11,083           13,951

Cash and cash equivalents at beginning of year                              11,019            1,379           10,877
                                                                         ---------        ---------        ---------

Cash and cash equivalents at end of year                                 $  24,828        $  12,462        $  24,828
                                                                         =========        =========        =========

Supplemental disclosure of cash flow information:

     Interest paid                                                       $  56,123        $   1,915        $  56,123
                                                                         =========        =========        =========

     Income taxes paid                                                   $      --        $      --        $   1,081
                                                                         =========        =========        =========

</TABLE>

<PAGE>

                          NOTES TO FINANCIAL STATEMENTS

A. BASIS OF PRESENTATION

     The accompanying unaudited financial statements have been prepared in
accordance with generally accepted accounting principles for interim financial
information and with the instructions to Form 10-QSB and Article 10 of
Regulation S-X. Accordingly, they do not include all of the information and
footnotes required by generally accepted accounting principles for complete
financial statements. In the opinion of management, all adjustments (consisting
of normal recurring accruals) considered necessary for a fair presentation have
been included. Consolidated financial statements have been prepared due to the
combination of Vital Health Technologies, Inc. and Caribbean American Health
Resorts, Inc. Operating results for the three-month period ended June 30, 2003
are not necessarily indicative of the results that may be expected for the year
ended December 31, 2003. For further information, refer to the financial
statements and footnotes thereto included in the Company's Form 10-KSB for the
year ended December 31, 2002.

Nature of Business

     The Company was incorporated on April 1, 1960, under the laws of the State
of Minnesota. On September 26, 2000, the Company changed its name to Vital
Health Technologies, Inc. Formerly the Company was known as Vital Heart Systems,
Inc.

     The Company has focused its efforts on the design and marketing of a
non-invasive, stress-free coronary artery disease (CAD) detection device called
a Variance Cardiograph.

     From 1993 to 1998 the Company struggled with a variety of financial
difficulties, which limited operations. Since 1998 through March 2003 the
Company has worked with a Minnesota finance and business development firm,
Aurora Capital Management, LLC and its affiliates in an effort to revitalize the
Company.

     In March 2003, the Company executed and entered into a Share Exchange
Agreement (the "Exchange Agreement"), with Caribbean American Health Resorts,
Inc. Pursuant to the Exchange Agreement, on the closing date, the Company will
acquire all of the issued and outstanding equity interests of Caribbean American
Health Resorts,Inc. As consideration for the shares Caribbean American Health
Resorts, Inc, the Company will issue 8,109,709 shares of its common stock to the
shareholders of Caribbean American Health Resorts, Inc. Subsequent to the
closing of this transaction, and a concurrent transaction whereby certain
shareholders of the Company are selling 1,640,709 common shares, the remaining
stockholders of the Company shall retain 250,000 shares, or 2 1/2% of the issued
and outstanding common stock of the Company on an anti-dilutive basis (only for
90 days after the closing). As part of this transaction, certain existing
shareholders of the Company shall form a separate entity for the sole purpose of
purchasing the heart screening technology of the Company in exchange for
returning to the Company 1,850,000 shares of Company common stock presently held
by such shareholders.

     The Company's common stock currently trades on the NASD's OTC Bulletin
Board exchange under the ticker symbol CAHR.

Development Stage Company

     The Company has devoted the majority of its efforts to: maintenance of the
corporate status; settlement of liabilities; technology development and the
search for a viable method of operations and/or merger candidate.

<PAGE>

     Since 1998 the Company has been fully dependent on Aurora and its
affiliates for the maintenance of its corporate status and to provide all
managerial assistance and working capital support for the Company.

     In 2001 the Company successfully developed a new prototype for its Variance
Cardiograph heart disease testing device that shortens the test time from the
original 45-minute version to 10-minutes, while at the same time reducing the
cost of manufacturing significantly. The Company completed field-testing and has
systems installed at two locations in the St. Paul/Minneapolis area for
evaluation purposes.

     The Company holds and maintains a patent on its Variance Cardiography
technology that was issued in 1993.

     On January 30, 2002 the Company entered into an agreement with a Texas
based finance and consulting firm, Focus Tech Investments, Inc. (FTI) where FTI
will provide periodic financing and will seek out potential merger/acquisition
candidates for the Company. The original agreement with FTI was to expire on
August 30, 2002. The Company and FTI have agreed to an extension for an
additional 180 days as the Company is having discussions with candidates FTI has
introduced.

     On April 23, 2002 the Company entered into a stock purchase agreement with
Templar Comptier, Ltd whereas the Company sold 1,146,250 shares of its common
stock for $350,000. Templar Comptier has paid $50,000 in cash for 146,250 shares
that have been delivered and the Company holds a 180-day note for $300,000 with
the remaining 1,000,000 shares being held as collateral against the note.

     The Company utilized the proceeds for ongoing administrative costs, debt
payment and to finance merger/acquisition expenses. The Company filed an SB-2
registration with the SEC for the shares issued to Templar Comptier, Ltd. and
386,224 shares that were previously issued to shareholders of Vital Health
Technologies.

     In March 2003, the Company executed and entered into a Share Exchange
Agreement (the "Exchange Agreement"), with Caribbean American Health Resorts,
Inc. Pursuant to the Exchange Agreement, on the closing date, the Company will
acquire all of the issued and outstanding equity interests of Caribbean American
Health Resorts,Inc. As consideration for the shares Caribbean American Health
Resorts, Inc, the Company will issue 8,109,709 shares of its common stock to the
shareholders of Caribbean American Health Resorts, Inc. Subsequent to the
closing of this transaction, and a concurrent transaction whereby certain
shareholders of the Company are selling 1,640,709 common shares, the remaining
stockholders of the Company shall retain 250,000 shares, or 2 1/2% of the issued
and outstanding common stock of the Company on an anti-dilutive basis (only for
90 days after the closing). As part of this transaction, certain existing
shareholders of the Company shall form a separate entity for the sole purpose of
purchasing the heart screening technology of the Company in exchange for
returning to the Company 1,850,000 shares of Company common stock presently held
by such shareholders.

<PAGE>

Item 2. Management's Discussion and Analysis of Financial Condition and Plan of
Operation
-------------------------------------------------------------------------------

Three Months Ended September 30, 2003 and September 30.2002

The company generated $10,500 for three months ended September 30, 2003 as
compared to $0 revenue for the same period September 2002. Cost of Sales for the
three months ended September 30, 2003 and 2002 were $0 and $0 respectively.

General and Administrative expenses for the three months ended September 30,
2003 were $33,285 as compared to $11,073 in the same period of 2002.

The company had interest expense in the amount of $0 for the three months ended
September 30, 2003 as compared to the interest expense of $2,437 for the three
months ended September 30 2002.

As result of the foregoing, the company realized a net loss of $22,785 for the
three months ended September 30, 2003 as compared to a net loss of $13,510 for
the same period 2002

Liquidity and Capital Resources

At September 30, 2003, the company had working capital of $24,828 as compared to
$11,019 at December 31, 2002. The change was due primarily to a merger with
Caribbean American Health Resorts, Inc.

Plan for the next 12 months

The management of the company plans for the next 12 months are continue to
handle administrative and reporting requirements of a public company. The
company plans to acquire beach front hotel properties on the island of Barbados.
It has entered an agreement in principle with Royal Caribbean Hotels for the
purchase of approximately 21/2 acres of beach front property at Hastings, Christ
Church, Barbados. The company is also awaiting permission form the Government of
Barbados to allow the physicians and surgeons to perform services on the island
of Barbados. It is expected that this permission and the purchase agreement for
acquisition of property will be completed will be granted by December 31, 2003.

Item 3.  Controls and Procedures
--------------------------------

     Within the 90 days prior to the date of this Form 10-QSB, the Company
carried out an evaluation, under the supervision and with the participation of
the Company's management, including the Company's Chief Executive Officer and
Chief Financial Officer, of the effectiveness of the design and operation of the
Company's disclosure controls and procedures pursuant to Exchange Act Rule
13a-14. Based upon that evaluation, the Company's Chief Executive Officer/Chief
Financial Officer concluded that the Company's disclosure controls and
procedures are effective in timely alerting them to material information
relating to the Company required to be included in the Company's periodic SEC
filings. There have been no significant changes in the Company's internal
controls or in other factors, which could significantly affect internal controls
subsequent to the date the Company carried out its evaluation.


<PAGE>

Forward-Looking Statement Notice

     When used in this report, the words "may," "will," "expect," "anticipate,"
"continue," "estimate," "project," "intend," and similar expressions are
intended to identify forward-looking statements within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act
of 1934 regarding events, conditions, and financial trends that may affect our
future plans of operations, business strategy, operating results, and financial
position. Persons reviewing this report are cautioned that any forward-looking
statements are not guarantees of future performance and are subject to risks and
uncertainties and that actual results may differ materially from those included
within the forward-looking statements as a result of various factors. Such
factors are discussed above and also include general economic factors and
conditions that may directly or indirectly impact our financial condition or
results of operations.

PART II - OTHER INFORMATION


Item 6.  Exhibits and Reports on Form 8-K.

(a) Exhibits required by Item 601 of Regulation S-B

     31.1 Certification pursuant to Section 302 of Sarbanes Oxley Act of 2002

     32.1 Certification pursuant to Section 906 of Sarbanes Oxley Act of 2002

(b) Reports on Form 8-K.



                                   SIGNATURES

        In accordance with the requirements of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

                                   Vital Health Technologies, Inc.

Date: November 14, 2003            By:  /s/  Halton Martin
                                   =================================
                                   Halton Martin, Director,
                                   Chief Financial Officer and
                                   Chief Executive Officer


                                        8